A detailed history of Sigma Planning Corp transactions in Regenxbio Inc. stock. As of the latest transaction made, Sigma Planning Corp holds 27,575 shares of RGNX stock, worth $300,567. This represents 0.02% of its overall portfolio holdings.

Number of Shares
27,575
Previous 12,430 121.84%
Holding current value
$300,567
Previous $223,000 160.54%
% of portfolio
0.02%
Previous 0.02%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 01, 2024

BUY
$12.17 - $24.61 $184,314 - $372,718
15,145 Added 121.84%
27,575 $581,000
Q4 2023

Feb 01, 2024

SELL
$12.89 - $20.82 $283,721 - $458,269
-22,011 Reduced 63.91%
12,430 $223,000
Q3 2023

Nov 06, 2023

SELL
$16.46 - $19.99 $246 - $299
-15 Reduced 0.04%
34,441 $566,000
Q2 2023

Aug 01, 2023

BUY
$17.23 - $21.71 $79,430 - $100,083
4,610 Added 15.45%
34,456 $688,000
Q1 2023

May 05, 2023

BUY
$18.08 - $24.55 $129,723 - $176,146
7,175 Added 31.65%
29,846 $564,000
Q4 2022

Jan 24, 2023

SELL
$20.4 - $24.73 $2,182 - $2,646
-107 Reduced 0.47%
22,671 $0
Q3 2022

Nov 10, 2022

SELL
$22.29 - $35.04 $46,140 - $72,532
-2,070 Reduced 8.33%
22,778 $602,000
Q2 2022

Aug 11, 2022

BUY
$19.35 - $35.04 $3,424 - $6,202
177 Added 0.72%
24,848 $614,000
Q1 2022

Apr 20, 2022

SELL
$24.62 - $34.31 $615 - $857
-25 Reduced 0.1%
24,671 $819,000
Q4 2021

Feb 02, 2022

SELL
$30.19 - $40.28 $3,532 - $4,712
-117 Reduced 0.47%
24,696 $808,000
Q3 2021

Oct 28, 2021

BUY
$29.09 - $45.68 $26,355 - $41,386
906 Added 3.79%
24,813 $1.04 Million
Q2 2021

Aug 13, 2021

BUY
$32.46 - $40.48 $4,609 - $5,748
142 Added 0.6%
23,907 $929,000
Q1 2021

May 06, 2021

BUY
$33.61 - $49.95 $798,741 - $1.19 Million
23,765 New
23,765 $811,000
Q3 2018

Nov 07, 2018

SELL
$65.0 - $82.15 $206,700 - $261,237
-3,180 Closed
0 $0
Q2 2018

Aug 02, 2018

BUY
$27.2 - $74.35 $86,496 - $236,432
3,180 New
3,180 $228,000

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $471M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Sigma Planning Corp Portfolio

Follow Sigma Planning Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sigma Planning Corp, based on Form 13F filings with the SEC.

News

Stay updated on Sigma Planning Corp with notifications on news.